Compare BIO-TECHNE Corp (TECH) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Wheaton Precious Metals Corp — how do they compare? BIO-TECHNE Corp trades at $72.17 (market cap $11.24B), while Wheaton Precious Metals Corp trades at $134.31 (market cap $60.46B). The key difference: Wheaton Precious Metals Corp is far larger — about 5.4× BIO-TECHNE Corp's market cap, and Wheaton Precious Metals Corp pays the higher dividend (0.58%). Which is the better fit depends on your goals.
| TECH | WPM | |
|---|---|---|
Market Cap | $11.24B | $60.46B |
Sector | Health | Basic Materials |
52-Week High | $72.29 | $165.72 |
52-Week Low | $43.31 | $91.02 |
Enterprise Value | $11.32B | $62.34B |
Dividend Yield | 0.44% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Wheaton Precious Metals (WPM) trades at $134.20, up 7.1% in 24 hours, near its pivot point of $134. The stock shows strong momentum with bullish moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.19 versus $1.15 estimated, driven by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income margins exceeding 64%, while valuation ratios like P/E of 29.77 reflect premium pricing. Analysts maintain an 80% buy rating with a $161.75 consensus target.
Outlook remains positive due to robust cash flow growth and exposure to rising gold/silver prices, but risks include commodity volatility and high valuations. Institutional buying supports upside, though technical indicators suggest near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
